L. Lamoreaux

Publications24
h-index12
Citations7,892
Highly Influential Citations202
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. O'Brien
  • 330 Publications • 37,286 Citations
  • E. Garofalo
  • 40 Publications • 4,385 Citations
  • P. Dyck
  • 780 Publications • 42,902 Citations
  • B. Abou-Khalil
  • 272 Publications • 10,430 Citations
  • Publications
  • Influence
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
TLDR
Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life.
Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
TLDR
Pregabalin at 450 mg/day was efficacious for the treatment of FMS, reducing symptoms of pain, disturbed sleep, and fatigue compared with placebo and was well tolerated and improved global measures and health-related quality of life.
Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial.
Efficacy and safety of zonisamide: results of a multicenter study
Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial
TLDR
Pregabalin 600 mg/d (300 mg BID) effectively reduced pain, was well tolerated, and had no statistically significant or clinically meaningful effect on NC in patients with painful DPN.
Gabapentin as Add‐On Therapy in Children with Refractory Partial Seizures: A 12‐Week, Multicentre, Double‐Blind, Placebo‐Controlled Study
TLDR
The objective was to evaluate the efficacy and safety of gabapentin as add‐on therapy for refractory partial seizures in paediatric patients aged 3–12 years.
Gabapentin in Naive Childhood Absence Epilepsy: Results From Two Double-Blind, Placebo-Controlled, Multicenter Studies
TLDR
Gabapentin monotherapy at dosages ranging from 9.7 through 19.1 mg/kg/day is well tolerated in pediatric patients aged 4 through 12 years with absence epilepsy and may have contributed to the lack of demonstrable efficacy.
Effect of gabapentin (neurotonin®) on mood and well-being in patients with epilepsy
...
1
2
3
...